Joseph Palascak

Joseph E Palascak

Professor-Emeritus

Vontz Center

3116

COM IM Hematology/Oncology Division - 0562

Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati, Ohio 45267

Education

Medical Degree, Thomas Jefferson University, Jefferson Medical College 1968

Residency, Thomas Jefferson University Hospital 1971 (Internal Medicine)

Fellowship , Thomas Jefferson University Philadelphia, PA, 1974 (Hematologic Research )

BS, Duquesne University Pittsburgh, PA, 1964 (Chemistry)

Research and Practice Interests

Hemophilia, Sickle Cell Disease, Hematology Oncology

UC Health Clinical Focus

Hematology

UC Health Specialities

Hematology

Internal Medicine

Certifications

American Board of Internal Medicine (Hematology)

06/27/1978

American Board of Internal Medicine

06/18/1975

Research Support

Grant: #5 R01 HL068429-04 Investigators:Palascak, Joseph 04-01-2006 -09-30-2007 National Heart, Lung and Blood Institute Impact of HIV on Hepatitis C Infection in Hemophilia Role:PI $9,000.00 Closed Level:Federal

Grant: #SRS 001242 Investigators:Palascak, Joseph 06-01-2006 -05-31-2008 Hemophilia Foundation of Michigan Cascade Hemophilia Consortium Role:PI $69,028.00 Closed Level:Private Non-Profit

Investigators:Palascak, Joseph 09-30-2004 -09-29-2006 Centers for Disease Control and Prevention CDC Prevention Grant Role:PI $13,600.00 Closed Level:Federal

Grant: #HFM - 6H30MC0015 Investigators:Palascak, Joseph 06-01-2005 -05-31-2010 Centers for Disease Control and Prevention Region V-East Comprehensive Care Network for Bleeding Disorders Role:PI $53,339.00 Closed Level:Federal

Grant: #SRS 001869 Investigators:Palascak, Joseph 09-30-2005 -09-29-2010 Centers for Disease Control and Prevention CDC Prevention Grant Role:PI $73,287.00 Closed Level:Federal

Grant: #SRS 001926 Investigators:Palascak, Joseph 06-01-2005 -05-31-2007 Hemophilia Foundation of Michigan Cascade Hemophilia Consortitum 6/1/05 - 5/31/06 Role:PI $29,389.00 Closed Level:Private Non-Profit

Grant: #31-3-002-1-AV-03-05-A0-S0-E0 Investigators:Palascak, Joseph 07-01-2002 -06-30-2003 Ohio Department of Health Hemophilia Comprehensive Care and Hemophilia Insurance Pilot Program Role:PI $63,973.00 Closed Level:State of Ohio

Investigators:Palascak, Joseph 06-01-2003 -05-31-2004 Hemophilia Foundation of Michigan Cascade Hemophelia Consortium Role:PI $24,000.00 Closed Level:Private Non-Profit

Investigators:Palascak, Joseph 06-01-2004 -08-31-2005 Hemophilia Foundation of Michigan Cascade Hemophilia Consortium Role:PI $27,569.00 Closed Level:Private Non-Profit

Grant: #CHC-01-05-A0-S0-E0 Investigators:Palascak, Joseph 01-01-2000 -03-31-2002 Hemophilia Foundation of Michigan Cascade Hemophilia Consortium Role:PI $17,342.00 Closed Level:Private Non-Profit

Grant: #HFOM-01-MCHB-14-A0-S0-E0 Investigators:Palascak, Joseph 06-01-2000 -05-31-2002 Bureau of Primary Health Care AIDS Risk Reduction Adult Hemophilia Program Role:PI $16,401.00 Closed Level:Federal

Grant: #31-4-01-F-AV-03-A0-S0-E0 Investigators:Palascak, Joseph 07-01-2000 -06-30-2001 Ohio Department of Health Hemophilia Comprehensive Care and Hemophilia Insurance Pilot Program Role:PI $124,800.00 Closed Level:State of Ohio

Investigators:Palascak, Joseph 10-01-2000 -08-31-2004 Centers for Disease Control and Prevention AIDS Risk Reduction Adult Hemophilia Program Role:PI $48,091.00 Closed Level:Federal

Grant: #31-3-002-1-AV-02-04-A0-S0-E0 Investigators:Palascak, Joseph 07-01-2001 -06-30-2002 Ohio Department of Health Hemophilia Comprehensive Care and Hemophilia Insurance Pilot Program Role:PI $113,674.00 Closed Level:State of Ohio

Investigators:Palascak, Joseph 01-01-2002 -05-31-2003 Hemophilia Foundation of Michigan Cascade Hemophelia Consortium Role:PI $34,153.00 Closed Level:Private Non-Profit

Investigators:Palascak, Joseph 06-01-2002 -05-31-2005 Maternal and Child Health Bureau Region V-East Comprehensive Care Network for Bleeding Disorders Role:PI $27,041.00 Closed Level:Federal

Investigators:Palascak, Joseph 04-01-2001 -10-31-2005 National Cancer Institute Second Multicenter Hemophelia Cohort Study (MHCS - II) Role:PI $19,500.00 Closed Level:Federal

Grant: #HFOM-01-MCHB-11-A0-S0-E0 Investigators:Palascak, Joseph 10-01-1996 -08-31-1999 Bureau of Primary Health Care AIDS Risk Reduction Adult Hemophilia Program Role:PI $24,800.00 Closed Level:Federal

Grant: #HFOM-02-CDC-11-A0-S0-E0 Investigators:Palascak, Joseph 10-01-1996 -09-30-1999 Centers for Disease Control and Prevention AIDS Risk Reduction Adult Hemophilia Program Role:PI $33,220.00 Closed Level:Federal

Grant: #CHC-01-03-A0-S0-E0 Investigators:Palascak, Joseph 01-01-1998 -12-31-1999 Hemophilia Foundation of Michigan University of Cincinnati Adult Hemophilia Treatment Center Role:PI $11,700.00 Closed Level:Private Non-Profit

Grant: #ODH-31-4-01-F-AV-02-A0-S0-E0 Investigators:Palascak, Joseph 07-01-1998 -06-30-2000 Ohio Department of Health Ohio Hemophilia Program Role:PI $247,000.00 Closed Level:State of Ohio

Grant: #HFOM-01-MCHB-12-A0-S0-E0 Investigators:Palascak, Joseph 09-01-1999 -05-31-2000 Bureau of Primary Health Care AIDS Risk Reduction Adult Hemophilia Program Role:PI $7,000.00 Closed Level:Federal

Grant: #HFOM-02-CDC-12-A0-S0-E0 Investigators:Palascak, Joseph 10-01-1999 -09-30-2000 Centers for Disease Control and Prevention AIDS Risk Reduction Adult Hemophilia Program Role:PI $13,625.00 Closed Level:Federal

Grant: #SRS 005962 Investigators:Palascak, Joseph 06-01-2008 -08-31-2009 Hemophilia Foundation of Michigan 2008-2009 Cascade Hemophilia Consortium Role:PI $36,610.00 Closed Level:Private Non-Profit

Grant: #srs006950 Investigators:Palascak, Joseph 06-01-2010 -05-31-2011 Hemophilia Foundation of Michigan 2010-2011 Cascade Hemophilia Consortium Role:PI $36,759.00 Closed Level:Private Non-Profit

Grant: #MCHB Investigators:Palascak, Joseph 06-01-2010 -05-31-2011 Maternal and Child Health Bureau 2010-2011MCHB Grant Region V-East Comprehensive Care Network for Bleeding Disorders Role:PI $11,000.00 Closed Level:Federal

Grant: #U01 DD00203-05 Investigators:Palascak, Joseph 10-01-2010 -09-30-2011 Centers for Disease Control and Prevention Region V East Network for Comprehensive Care and the Prevention of the Complications of Hemophilia Role:PI $14,500.00 Closed Level:Federal

Grant: #2011-2012 MCHB Investigators:Palascak, Joseph 06-01-2011 -05-31-2012 Maternal and Child Health Bureau Region V East Network for Comprehensive Care and the Prevention of the Complications of Hemophilia Role:PI $11,000.00 Closed Level:Federal

Grant: #CDC11-12-HTC434/ ATHN2001-VE-1 Investigators:Palascak, Joseph 09-30-2011 -09-29-2014 Centers for Disease Control and Prevention Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders Role:PI $12,000.00 Closed Level:Federal

Grant: #Cascade 12-13 Investigators:Palascak, Joseph 06-01-2012 -07-31-2013 Cascade Hemophilia Consortium 2012-2013 Cascade Agreement for Region V East Comprehensive Care Network for Bleeding Disorders Role:PI $39,882.00 Active Level:Private Non-Profit

Grant: #MCHB \ 1-H30MC24047-01-00 Investigators:Palascak, Joseph 06-01-2012 -05-31-2013 Health Resources and Services Administration 2012-2013 Hemophilia Foundation of Michigan Agreement for Region V East Comprehensive Care Network for Bleeding Disorders Role:PI $11,000.00 Active Level:Federal

Grant: #ATHN20011001-VE-2 / CDC12-13-HTC434 Investigators:Palascak, Joseph 09-30-2012 -09-29-2014 Centers for Disease Control and Prevention CDC12-13-HTC434 Role:PI $12,000.00 Active Level:Federal

Grant: #Cascade 2013-14 Investigators:Palascak, Joseph 06-01-2013 -05-31-2014 Hemophilia Foundation of Michigan Cascade Hemophilia Consortium Role:PI $55,852.00 Active Level:Private Non-Profit

Grant: #MCHB 2013-14 Investigators:Palascak, Joseph 06-01-2013 -05-31-2014 Maternal and Child Health Bureau 2013-2014 Maternal and Child Health Bureau (MCHB) Role:PI $11,000.00 Active Level:Federal

Grant: #CDC13-14-HTC434 / ATHN20011001-VE-3 Investigators:Palascak, Joseph 09-30-2013 -09-29-2014 Centers for Disease Control and Prevention CDC12-13-HTC434 Role:PI $12,000.00 Awarded Level:Federal

Grant: #Grant Award and Services Contract Investigators:Palascak, Joseph 06-01-2014 -05-31-2015 Cascade Hemophilia Consortium 2014-2015 Cascade Hemophilia Consortium Role:PI $61,614.00 Awarded Level:Private Non-Profit

Grant: #MCHB 2014-2015/1-H30MC24047-01-01 Investigators:Palascak, Joseph 06-01-2014 -05-31-2015 Maternal and Child Health Bureau 2014 - 2015 Maternal and Child Health Bureau (MCHB) Role:PI $11,000.00 Active Level:Federal

Grant: #CDC14-15-HTC434 Investigators:Palascak, Joseph 09-30-2014 -09-29-2015 Centers for Disease Control and Prevention CDC14-15-HTC434 Role:PI $14,000.00 Active Level:Federal

Grant: #2015-16 CASCADE Investigators:Palascak, Joseph 06-01-2015 -05-31-2016 Hemophilia Foundation of Michigan CASCADE 2015-2016 Role:PI $69,161.00 Active Level:Private Non-Profit

Grant: #MCHB 2015-2016/H30MC24047-04-01 Investigators:Palascak, Joseph 06-01-2015 -05-31-2016 Maternal and Child Health Bureau 2015-2016 Maternal and Child Health Bureau (MCHB) Contract Role:PI $11,000.00 Awarded Level:Federal

Grant: #Subaward #15-16-434/NU27DD001155-01-00 Investigators:Palascak, Joseph 09-30-2015 -09-29-2016 Hemophilia Foundation of Michigan CDC15-16-HTC434 Role:PI $18,000.00 Active Level:Private Non-Profit

Grant: #2016-2017 Cascade Investigators:Palascak, Joseph 06-01-2016 -05-31-2017 Hemophilia Foundation of Michigan 2016-2017 Cascade Hemophilia Consortium Role:PI $99,161.00 Active Level:Private Non-Profit

Grant: #Subaward No. CDC 16-17-434 / U27DD001155 Investigators:Palascak, Joseph 09-30-2016 -09-30-2017 Centers for Disease Control and Prevention 2016-2017 CDC/HFM Community Counts: Public Health Surveillance for Bleeding Disorders Role:PI $18,000.00 Active Level:Federal

Grant: #MCHB 2016-2017/H30MC24047-05-00 Investigators:Palascak, Joseph 06-01-2016 -05-31-2017 Maternal and Child Health Bureau 2016-2017 Maternal and Child Health Bureau (MCHB) Contract Role:PI $11,000.00 Active Level:Federal

Grant: #HFM Cascade 2017-2018 Investigators:Palascak, Joseph 06-01-2017 -05-31-2018 Cascade Hemophilia Consortium 2017-2018 Cascade Role:PI $99,161.00 Active Level:Private Non-Profit

Grant: #MCHB 434 17-18/2H30MC24047-06-00 Investigators:Palascak, Joseph 06-01-2017 -05-31-2018 Maternal and Child Health Bureau 2017-2018 Maternal and Child Health Bureau (MCHB) Contract Role:PI $15,000.00 Active Level:Federal

Grant: #CDC 17-18-434 / 5 NU27DD001155-03-00 Investigators:Palascak, Joseph 09-30-2017 -09-29-2018 Centers for Disease Control and Prevention CDC17-18-HTC434 Role:PI $19,300.00 Awarded Level:Federal

Grant: #Cascade 18-19 Investigators:Palascak, Joseph 06-01-2018 -05-31-2019 Hemophilia Foundation of Michigan 2018-2019 Cascade Role:PI $151,817.00 Active Level:Private Non-Profit

Grant: #434 18-19/H30MC24047-07-00 Investigators:Palascak, Joseph 06-01-2018 -05-31-2019 Maternal and Child Health Bureau 2018-2019 Maternal and Child Health Bureau (MCHB) Contract Role:PI $15,000.00 Active Level:Federal

Grant: #CDC18-19-HTC434 sub CDC Investigators:Palascak, Joseph 09-30-2018 -09-29-2019 Centers for Disease Control and Prevention CDC18-19-HTC434 Role:PI $19,300.00 Awarded Level:Federal

Grant: #ATHN2018-ATHN 7_Genetech Investigators:Palascak, Joseph 03-01-2019 -03-31-2024 Genentech, Inc. A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia (ATHN 7) Role:PI $6,500.00 Awarded Level:Industry

Grant: #ATHN2016-ATHN5-434-1 sub HoG Investigators:Palascak, Joseph 01-01-2018 -09-30-2020 Hemophilia of Georgia Hepatitis C Virus (HCV) Outcomes After Treatment with DAA in Patients with Bleeding Disorders (ATHN 5: HCV Outcomes Study) Role:PI $20,350.00 Awarded Level:Private Non-Profit

Grant: #Cascade 19-20 Investigators:Palascak, Joseph 06-01-2019 -05-31-2020 Hemophilia Foundation of Michigan 2019-2020 Cascade Role:PI $147,149.63 Active Level:Private Non-Profit

Grant: #MCHB 434 19-20 / H30MC24047 Investigators:Palascak, Joseph 06-01-2019 -05-31-2020 Maternal and Child Health Bureau 2019-2020 Cascade Role:PI $15,000.00 Active Level:Federal

Grant: #CDC19-20-HTC434 Investigators:Palascak, Joseph 09-30-2019 -09-29-2020 Centers for Disease Control and Prevention CDC19-20-HTC434 Role:PI $19,242.93 Awarded Level:Federal

Grant: #2020-2021 Cascade Investigators:Palascak, Joseph 06-01-2020 -05-31-2021 Hemophilia Foundation of Michigan Cascade 2020-2021 Role:PI $175,619.58 Awarded Level:Private Non-Profit

Publications

Peer Reviewed Publications

Yasin,Z.; Retzinger,G.; Palascak,J. (2000. )Thrombosis refractory to urokinase in a patient with pnh and factor v leiden mutation. is there a role for plasmaphersis? .Blood, ,98 (11 PART II ),

Yasin,Z.; Quick,D.; Thiagarajan,P.; Spoor,D.; Caraveo,J.; Palascak,J. (1999. )Light-chain paraproteins with lupus anticoagulant activity .American Journal of Hematology, ,62 (2 ),99 -102

Erslev,A.J.; Palascak,J.E.; Shaikh,B.S.; Martinez,J. (1998. )Platelet kinetics in autosomal dominant macrothrombocytopenia .Journal of Laboratory and Clinical Medicine, ,131 (6 ),488 -495

Franco,R.; Barker-Gear,R.; Silberstein,E.; Mayfield,G.; Weiner,M.; Palascak,J.; Green,R. (1992. )Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival .Advances in Experimental Medicine and Biology, ,326 ,325 -331

Cotto,M.A.; Lutomski,D.M.; Palascak,J.E.; Fant,W.K.; LaFrance,R.J. (1990. )Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study .Journal of Parenteral and Enteral Nutrition, ,14 (2 ),201 -203

Martelo,O.J.; Palascak,J.E. (1988. )Platelet dysfunction and bleeding associated with beta-lactam antibiotics. Journal of Infectious Diseases, ,157 (5 ),1100 -1101

Lutomski,D.M.; Palascak,J.E.; Bower,R.H. (1987. )Warfarin resistance associated with intravenous lipid administration .Journal of Parenteral and Enteral Nutrition, ,11 (3 ),316 -318

Miller,M.A.; Palascak,J.E.; Thompson,M.R. (1985. )A modified sds agarose gel method for determining factor viii von willebrand factor multimers using commercially available reagents .Thrombosis Research, ,39 (6 ),777 -780

Martinez,J.; Keane,P.M.; Gilman,P.B.; Palascak,J.E. (1983. )The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease .Annals of the New York Academy of Sciences, ,Vol. 408 ,388 -396

Martinez,J.; MacDonald,K.A.; Palascak,J.E. (1983. )The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains .Blood, ,61 (6 ),1196 -1202

Lusher,J.M.; Shapiro,S.S.; Palascak,J.E. (1980. )Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor viii. a multicenter therapeutic trial .New England Journal of Medicine, ,303 (8 ),421 -425

Lusher,J.M.; Shapiro,S.S.; Palascak,J.E.; Rao,A.V.; Levine,P.H.; Blatt,P.M. (1980. )Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, ,93 ,175 -181

Martinez,J.; Palascak,J.E.; Kwasniak,D. (1978. )Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease .Journal of Clinical Investigation, ,61 (2 ),535 -538

Palascak,J.E.; Shapiro,S.R. (1977. )Anti-factor viii anamnesis after factor ix complex. New England Journal of Medicine, ,297 (25 ),1403

Palascak,J.E.; Martinez,J. (1977. )Dysfibrinogenemia associated with liver disease .Journal of Clinical Investigation, ,60 (1 ),89 -95

Martinez,J.; Palascak,J.; Peters,C. (1977. )Functional and metabolic properties of human asialofibrinogen .Journal of Laboratory and Clinical Medicine, ,89 (2 ),367 -377

Martinez,J.; Palascak,J.E.; Peters,C.L. (1975. )Proceedings: functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, ,34 (1 ),324

Beg,M.S.; Komrokji,R.S.; Ahmed,K.; Safa,M.M. (2008. )Oxaliplatin-induced immune mediated thrombocytopenia .Cancer Chemotherapy and Pharmacology, ,1 -3

Nahleh,Z.A.; Srikantiah,R.; Safa,M.; Jazieh,A.-R.; Muhleman,A.; Komrokji,R. (2007. )Male breast cancer in the veterans affairs population: a comparative analysis .Cancer, ,109 (8 ),1471 -1477

Jazieh,A.R.; Younas,A.; Safa,M.; Redmond,K.; Buncher,R.; Howington,J. (2007. )Phase i clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer .Cancer Investigation, ,25 (5 ),294 -298

Atiq,M.; Safa,M. (2007. )Recurrent hypoglycemia associated with poorly differentiated carcinoma of the liver .American Journal of Clinical Oncology: Cancer Clinical Trials, ,30 (2 ),213 -214

Lowy,A.M.; Firdaus,I.; Roychowdhury,D.; Redmond,K.; Howington,J.A.; Sussman,J.J.; Safa,M.; Ahmad,S.A.; Reed,M.F.; Rose,P.; James,L.; Jazieh,A.R. (2006. )A phase ii study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma .American Journal of Clinical Oncology: Cancer Clinical Trials, ,29 (6 ),555 -561

Safa,M.; Jazieh,A.-R. (2006. )Lack of a uniform approach to clinical research training for hematology oncology fellows .Journal of Cancer Education, ,21 (3 ),166 -168

Parameswaran,R.; Shapiro,A.D.; Gill,J.C.; Kessler,C.M.; Abshire,T.; Angiolillo,A.; Boggio,L.; Cohen,A.; DiMichele,D.; Hanna,W.; Hoots,K.; Hord,J.; Key,N.; Konkle,B.; Kouides,P.; Kurczynski,E.; Marks,P.; Palascak,J.; Pipe,S.; Ragni,M.; Rivard,G.; Shopnick,R.; Tarantino,M.; Valentino,L.; Watts,R.; White,G. (2005. )Dose effect and efficacy of rfviia in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry .Haemophilia, ,11 (2 ),100 -106

Goedert,J.J.; Siegel,J.; Miller,K.; Lederman,M.M.; Thompson,A.; Browning,B.; Gamerman,S.; McRedmond,K.; Withycombe,J.; Gruppo,R.; Stack,G.; Lusher,J.; Percy,L. (2005. )Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among persons with haemophilia, 2001-2003 .Haemophilia, ,11 (5 ),516 -528

Thompson,A.R.; Gill,J.C.; Ewenstein,B.M.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R. (2004. )Successful treatment for patients with von willebrand disease undergoing urgent surgery using factor viii/vwf concentrate (humate-p®) .Haemophilia, ,10 (1 ),42 -51

Gill,J.C.; Ewenstein,B.M.; Thompson,A.R.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R.; Binder,M.; Charbel,F.; Cooper,B.; Cornell,N.; Czapek,E.; Eisenberg,P.; Ewenstein,B.; Garcia-Ortiz,S.; Gastineau,D.; Gill,J.; Heggie,G.; Heisel,M.; Joist,H.; Knupp,C.; Lewis,B.; Matthews,D.; McKenna,P.; Murukutla,S.; Palascak,J.; Penner,J.; Powell,J.; Ritter,H.; Francisco,R.; Shapiro,A.; Simpson,T.; Stanek,M.; Thompson,A.R.; Tongol,J.; Waterbury,L.; White,G.; Young,R. (2003. )Successful treatment of urgent bleeding in von willebrand disease with factor viii/vwf concentrate (humate-p®): use of the ristocetin cofactor assay (vwf:rco) to measure potency and to guide therapy .Haemophilia, ,9 (6 ),688 -695

Safa,M.; Lower,E.E.; Hasselgren,P.O.; Hungness,E.S.; Gazder,P.; Aron,B.; Shaughnessy,E.A.; Yassin,R. (2002. )Bilateral synchronous breast cancer and her-2/neu overexpression .Breast Cancer Research and Treatment, ,72 (3 ),195 -201

Hungness,E.S.; Safa,M.; Shaughnessy,E.A.; Aron,B.S.; Gazder,P.A.; Hawkins,H.H.; Lower,E.E.; Seeskin,C.; Yassin,R.S.; Hasselgren,P.-O. (2000. )Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts .Surgery, ,128 (4 ),702 -707

Hickman,M.A.; Bernstein,I.L.; Palascak,J.E. (2000. )Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran .Annals of Allergy, Asthma and Immunology, ,84 (2 ),262 -263

Hickman, M A; Bernstein, I L; Palascak, J E (2000. )Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, ,84 (2 ),262-3

Erslev, A J; Palascak, J E; Shaikh, B S; Martinez, J (1998. )Platelet kinetics in autosomal dominant macrothrombocytopenia. The Journal of laboratory and clinical medicine, ,131 (6 ),488-95; discussion 4

Cotto, M A; Lutomski, D M; Palascak, J E; Fant, W K; LaFrance, R J Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study. JPEN. Journal of parenteral and enteral nutrition, ,14 (2 ),201-3

Martelo, O J; Palascak, J E (1988. )Platelet dysfunction and bleeding associated with beta-lactam antibiotics. The Journal of infectious diseases, ,157 (5 ),1100-1

Lutomski, D M; Palascak, J E; Bower, R H Warfarin resistance associated with intravenous lipid administration. JPEN. Journal of parenteral and enteral nutrition, ,11 (3 ),316-8

Miller, M A; Palascak, J E; Thompson, M R; Martelo, O J (1985. )A modified SDS agarose gel method for determining factor VIII von Willebrand factor multimers using commercially available reagents. Thrombosis research, ,39 (6 ),777-80

Martinez, J; Keane, P M; Gilman, P B; Palascak, J E (1983. )The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Annals of the New York Academy of Sciences, ,408 ,388-96

Martinez, J; MacDonald, K A; Palascak, J E (1983. )The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood, ,61 (6 ),1196-202

Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M (1980. )Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.The New England journal of medicine, ,303 (8 ),421-5

Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M (1980. )Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, ,93 ,175-81

Martinez, J; Palascak, J E; Kwasniak, D (1978. )Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.The Journal of clinical investigation, ,61 (2 ),535-8

Palascak, J E; Shapiro, S R (1977. )Anti-factor VIII anamnesis after factor IX complex. The New England journal of medicine, ,297 (25 ),1403

Palascak, J E; Martinez, J (1977. )Dysfibrinogenemia associated with liver disease.The Journal of clinical investigation, ,60 (1 ),89-95

Martinez, J; Palascak, J E; Peters, C L (1975. )Proceedings: Functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, ,34 (1 ),324

Agne, J L; Ahmad, N; Palascak, J E; Khaled, R; Karim, N A (2015. )VWD type 2N (Normandy) in two sisters.Haemophilia : the official journal of the World Federation of Hemophilia, ,21 (3 ),e223-5

Sherman K.E.;Ke R.;Rouster S.D.;Abdel-Hameed E.A.;Park C.;Palascak J.;Perelson A.S. (07-01-2016. )Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.Haemophilia, ,22 (4 ),543-548

Manco-Johnson M.J.;Bomgaars L.;Palascak J.;Shapiro A.;Geil J.;Fritsch S.;Pavlova B.G.;Gelmont D. (07-01-2016. )Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in.Thrombosis and Haemostasis, ,116 (1 ),58-68

Tsuang W.;Navaneethan U.;Ruiz L.;Palascak J.B.;Gelrud A. (04-01-2009. )Hypertriglyceridemic pancreatitis: Presentation and management.American Journal of Gastroenterology, ,104 (4 ),984-991

Goedert J.J.;Siegel J.;Miller K.;Lederman M.M.;Thompson A.;Browning B.;Gamerman S.;McRedmond K.;Withycombe J.;Gruppo R.;Stack G.;Lusher J.;Percy L.;Nugent D.;McDaniel M.;Manno C.;Butler R.;Wade A.;Angiolillo A.;Luban N.L.C.;Guelcher C.;Tarantino M.;Greer S.;Gill J.;Nelson J.;White G.;Fried M.;Grimsley A.L.;DiMichele D.;Goldberg I.;French J.;Hibner S.;Steinberg J.;Faust S.;Key N.;Hannemann V.;Kessler C.M.;Lee A.E.;Eyster M.E.;Galli K.;Jenkins G.;Bernstein Z.P.;Belling L.;Shapiro A.;Halley M.;Noblet P.;Jardine L.;Laudenbach L.;Lipton R.;Pece C.;Leissinger C.A.;Schmidt C.;Carr M.;Nolte M.;Manco-Johnson M.;Giambartolomei S.;Rubin S.H.;Belliveau D.;Aledort L.;McCarthy J.;Lemons R.;Bleak S.;Kraut E.;Witkoff L.;Sexauer C.;Kiplinger F.;Thompson A.;Cooper C.;Britton H.;Cobb K.;Reimers H.J.;Bagato J.A.;Powell J.S.;Herr M.;Scott K.;Hutter J.;Damiano M.L.;Navarro W.;Roth J.;Palascak J.;Sherman K.;Heffner M.;DiPaolo J.;Lammer M.;Iyer R.;Matthew P.;Schwartz M.;Konkle B.;Vijayanathan N.;Dugdale M.;Lilley D.;Hoots K.;Brown D.;Ullman M.;Neff A.;Klintworth S.;Sabio H.;Smith A.;Karafoulidou A. (09-01-2005. )Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among .Haemophilia, ,11 (5 ),516-528

Parameswaran R.;Shapiro A.;Gill J.;Kessler C.;Abshire T.;Angiolillo A.;Boggio L.;Cohen A.;DiMichele D.;Hanna W.;Hoots K.;Hord J.;Key N.;Konkle B.;Kouides P.;Kurczynski E.;Marks P.;Palascak J.;Pipe S.;Ragni M.;Rivard G.;Shopnick R.;Tarantino M.;Valentino L.;Watts R.;White G. (03-01-2005. )Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysi.Haemophilia, ,11 (2 ),100-106

Thompson A.R.;Gill J.C.;Ewenstein B.M.;Mueller-Velten G.;Schwartz B.A.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Bobrow S.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Green D.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Silver B.;Simpson T.;Stanek M.;Thompson A.R.;Tongol J.;Waterbury L.;White G.;Young R. (01-01-2004. )Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor.Haemophilia, ,10 (1 ),42-51

Gill J.;Ewenstein B.;Thompson A.;Mueller-Velten G.;Schwartz B.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Simpson T.;Stanek M.;Thompson A.;Tongol J.;Waterbury L.;White G.;Young R. (01-01-2003. )Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (.Haemophilia, ,9 (6 ),688-695

Yasin Z.;Quick D.;Thiagarajan P.;Spoor D.;Caraveo J.;Palascak J. (10-13-1999. )Light-chain paraproteins with lupus anticoagulant activity.American Journal of Hematology, ,62 (2 ),99-102

Franco R.;Barker-Gear R.;Silberstein E.;Mayfield G.;Weiner M.;Palascak J.;Green R. (12-01-1992. )Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased i .Advances in Experimental Medicine and Biology, ,326 ,325-331

Abildgaard C.F.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. (03-12-1981. )Hazards of Prothrombin-Complex Concentrates in Treatment of Hemophilia.New England Journal of Medicine, ,304 (11 ),670-671

Krauss J.S.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. (12-11-1980. )Treatment of Hemophilia with Prothrombincomplex Concentrates.New England Journal of Medicine, ,303 (24 ),1418

Lusher J.M.;Shapiro S.S.;Palascak J.E.;Rao A.V.;Levine P.H.;Blatt P.M. (08-21-1980. )Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII: A Multi.New England Journal of Medicine, ,303 (8 ),421-425

Martinez J.;Palascak J.;Peters C. (01-01-1977. )Functional and metabolic properties of human asialofibrinogen .The Journal of Laboratory and Clinical Medicine, ,89 (2 ),367-377

Contact Information

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2113
Fax: 513-558-2124
joseph.palascak@uc.edu